Related Experiment Video

Updated: Aug 17, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

An emerging role for calcium sensitisation in the treatment of heart failure

Leif Erhardt1

  • 1Lund University, Malmö University Hospital, 205 02 Malmö, Sweden. Leif.Erhardt@medforsk.mas.lUSe

Expert Opinion on Investigational Drugs
|July 12, 2005
PubMed

Insights

Levosimendan, a novel calcium sensitizer, improves cardiac function and hemodynamics in heart failure patients without increasing oxygen demand. Clinical trials confirm its benefits, with ongoing research into long-term prognosis.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure affects 2-3% of adults in developed countries.
  • Hemodynamic stability during decompensation requires intravenous vasodilators, diuretics, and inotropes.
  • Traditional inotropes can increase cardiac oxygen consumption and cause arrhythmias.

Purpose of the Study:

  • To review the role of calcium sensitizers, specifically levosimendan, in managing acute heart failure.
  • To highlight levosimendan's unique dual mechanism of action.
  • To discuss the clinical evidence and guidelines for levosimendan use.

Main Methods:

  • Review of clinical trials and European Society of Cardiology guidelines.
  • Analysis of levosimendan's pharmacological properties.
  • Assessment of hemodynamic effects and patient outcomes.

Main Results:

  • Levosimendan enhances cardiac output by stabilizing cardiac myofilaments via calcium-dependent mechanisms.
  • It exhibits vasodilatory effects by opening ATP-dependent potassium channels.
  • Clinical trials demonstrate beneficial hemodynamic effects, with ongoing studies on long-term prognosis.

Conclusions:

  • Levosimendan represents a promising new class of inotropes with a favorable safety profile.
  • Its dual mechanism offers advantages over traditional inotropes in acute heart failure management.
  • Updated guidelines recommend considering levosimendan for acute heart failure patients.

More Related Videos

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling08:29

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

Published on: August 1, 2016

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.